BioSpace News Archive

Study published in Molecular Cancer Therapeutics HSP90 targeting drives high tumor uptake and retention of a pan-PI3K inhibitor payload Lead conjugate shows xenograft efficacy superior to non-targeted pan-PI3K inhibitor Tumor targeting and payload masking prevent hyperglycemia seen with other PI3Kα inhibitors

Gary Reedy, chief executive officer for the American Cancer Society and American Cancer Society Cancer Action Network, announced that he will retire in April 2021.

Research Centers of America, Broward County’s largest independent research site, is currently conducting COVID-19 vaccine trials, implemented under Operation Warp Speed.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020.

Asahi Kasei has established industrial manufacturing technology for hyaluronic acid nanogel* as a new pharmaceutical excipient, and is providing samples to prospective customers in order to commercialize the product.

Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced today that it has reported its financial results for the three and six months ended June 30, 2020.

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced financial results for the second quarter ended June 30, 2020.

Luminex Corporation (Nasdaq: LMNX) today announced the retirement of its Chairman, G. Walter Loewenbaum, from its Board of Directors (“Board”) effective August 3, 2020.

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced that management will present at the William Blair Biotech Focus Conference on Thursday, August 6, 2020

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced full results of operations for the second quarter and first half of 2020, with net sales and adjusted earnings per share (EPS) in line with the preliminary results announced on July 9, 2020, and July 13, 2020.